Findling RL, et al. - The authors evaluated the short- and long-term efficacy and safety of pediatric-appropriate prolonged-release melatonin formulation (pedPRM) vs placebo for sleep disorders in children with autism spectrum disorder (ASD) and other neurodevelopmental disorders. For the short- and long-term treatment of sleep disorders, pedPRM was effective and safe in children with ASD and other neurodevelopmental disorders. In a population who could have significant difficulties in swallowing, the formulation was well tolerated. For children with ASD who suffered from sleep disorders refractory to sleep behavioral interventions, pedPRM could provide a safe evidence-based pharmacological intervention.